FDA Drug · D-0600-2021

Micardis Tablets, (telmisartan Tablets) 80 mg, 30 ct. per folding cartons, Rx only, NDC 0597-0041-37), Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877

Class II · Terminated

Subpotent Drug

Affected lots / codes — check yours against thisLot #860412; SEPT 2022

Recalling firm: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 15,198 bottles (30 tablets per bottle)
Distribution: AR, CO, CT, LA, NC, ND, NH, NJ, OH, PA and PR
Recall initiated: May 4, 2021
Classified: May 28, 2021
Terminated: October 14, 2021
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0600-2021%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →